A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
Launched by JANSSEN RESEARCH & DEVELOPMENT, LLC · Apr 11, 2025
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new treatment called JNJ-77242113 for people with moderate to severe plaque psoriasis, a skin condition that causes red, scaly patches. The main goal of the study is to see how effective JNJ-77242113 is compared to a placebo (which is an inactive treatment) and another medication called ustekinumab. If you or a loved one have been diagnosed with plaque psoriasis and have a significant amount of skin affected, you might be eligible to participate.
To qualify for the study, participants need to have a certain level of severity in their psoriasis, meaning at least 10% of their body surface area is affected. They should not have other forms of psoriasis or certain health issues that could interfere with the study. The trial is not yet recruiting participants, but if you join, you can expect close monitoring and care while receiving either the new treatment or one of the comparisons. This trial aims to gather important information to help improve treatments for plaque psoriasis in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), prior to the first administration of study intervention
- • Total body surface area (BSA) greater than or equal to (\>=)10 percent (%) at screening and baseline
- • Total psoriasis area and severity index (PASI) \>=12 at screening and baseline
- • Total investigator global assessment (IGA) \>=3 at screening and baseline
- • Candidate for phototherapy or systemic treatment for plaque psoriasis
- Exclusion Criteria:
- • Nonplaque form of psoriasis (for example \[e.g.\], erythrodermic, guttate, or pustular)
- • Current drug-induced psoriasis (e.g., a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
- • Known allergies, hypersensitivity, or intolerance to JNJ-77242113, ustekinumab, or its excipients
- • Major surgical procedure within 8 weeks before screening, or will not have fully recovered from surgical procedure, or has a surgical procedure planned during the time the participant is expected to participate in the study
- • Transplanted organ (with exception of a corneal transplant greater than \[\>\] 12 weeks before the first administration of study intervention)
About Janssen Research & Development, Llc
Janssen Research & Development, LLC, a subsidiary of Johnson & Johnson, is a leading pharmaceutical company dedicated to advancing innovative therapies in multiple therapeutic areas, including oncology, immunology, neuroscience, infectious diseases, and cardiovascular health. With a strong commitment to scientific excellence and patient-centered research, Janssen leverages cutting-edge technology and collaborative partnerships to drive the development of transformative treatments. The company is focused on addressing unmet medical needs through rigorous clinical trials and a robust pipeline, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Iowa City, Iowa, United States
Detroit, Michigan, United States
Boston, Massachusetts, United States
Odense, , Denmark
Troy, Michigan, United States
Zaragoza, , Spain
Bad Bentheim, , Germany
Aalborg, , Denmark
Hellerup, , Denmark
Rapid City, South Dakota, United States
Webster, Texas, United States
Melbourne, , Australia
Brussel, , Belgium
Feldkirch, , Austria
Portland, Oregon, United States
Fort Gratiot, Michigan, United States
Muenster, , Germany
San Diego, California, United States
Dallas, Texas, United States
Woolloongabba, , Australia
Wien, , Austria
Hamilton, Ontario, Canada
Granada, , Spain
Reading, , United Kingdom
Aarhus, , Denmark
Arlington, Texas, United States
Melbourne, , Australia
Ghent, , Belgium
Leuven, , Belgium
New York, New York, United States
Houston, Texas, United States
Szolnok, , Hungary
Witten, , Germany
Debrecen, , Hungary
Saint Joseph, Missouri, United States
Salford, , United Kingdom
Plainfield, Indiana, United States
Westmead, , Australia
Wakefield, , United Kingdom
Clayton, , Australia
Madrid, , Spain
Dresden, , Germany
Encinitas, California, United States
San Antonio, Texas, United States
Kecskemet, , Hungary
Bonn, , Germany
Wilmington, North Carolina, United States
Caba, , Argentina
Madrid, , Spain
Linz, , Austria
Ocala, Florida, United States
Harrow, , United Kingdom
Sylmar, California, United States
Kiel, , Germany
Santa Ana, California, United States
Pittsburgh, Pennsylvania, United States
Budapest, , Hungary
Brighton, Massachusetts, United States
San Antonio, Texas, United States
Philadelphia, Pennsylvania, United States
Berlin, , Germany
Valencia, , Spain
London, , United Kingdom
Kogarah, , Australia
Veszprem, , Hungary
Manises, , Spain
New York, New York, United States
Fountain Valley, California, United States
Mainz, , Germany
Liege, , Belgium
Sevilla, , Spain
Zaragoza, , Spain
Montreal, Quebec, Canada
Augsburg, , Germany
Gyula, , Hungary
Sevilla, , Spain
Gent, , Belgium
Barakaldo, , Spain
Markham, Ontario, Canada
Mill Creek, Washington, United States
Darmstadt, , Germany
Friedrichshafen, , Germany
Sacramento, California, United States
New Brighton, Minnesota, United States
Barrie, Ontario, Canada
Alpharetta, Georgia, United States
Debrecen, , Hungary
Kobenhavn Nv, , Denmark
Coral Gables, Florida, United States
Budapest, , Hungary
Roskilde, , Denmark
Caledonia, Michigan, United States
Villajoyosa, , Spain
Birmingham, Alabama, United States
Mayfield Heights, Ohio, United States
Ajax, Ontario, Canada
West Valley City, Utah, United States
Boardman, Ohio, United States
Miami, Florida, United States
Waterloo, Ontario, Canada
Kaposvar, , Hungary
Gyongyos, , Hungary
Maldegem, , Belgium
Kirksville, Missouri, United States
Barcelona, , Spain
Portland, Oregon, United States
Quebec, , Canada
Farmington, Connecticut, United States
Mitcham, , Australia
Rosario, , Argentina
Alicante, , Spain
Madrid, , Spain
Lodz, , Poland
Hodmezovasarhely, , Hungary
Buenos Aires, , Argentina
Caba, , Argentina
Langenau, , Germany
Lodz, , Poland
Tampa, Florida, United States
Bialystok, , Poland
Krakow, , Poland
Encino, California, United States
Oceanside, California, United States
London, Ontario, Canada
Bowling Green, Kentucky, United States
Wroclaw, , Poland
Poznan, , Poland
Warszawa, , Poland
Elblag, , Poland
Rocklin, California, United States
San Fernando, , Argentina
Dudley, , United Kingdom
Buenos Aires, , Argentina
Nashville, Tennessee, United States
Buenos Aires, , Argentina
Caba, , Argentina
Caba, , Argentina
Caba, , Argentina
Tucuman, , Argentina
Coorparoo, , Australia
Bramsche, , Germany
Mahlow, , Germany
Bialystok, , Poland
Katowice, , Poland
Olsztyn, , Poland
Warszawa, , Poland
Wroclaw, , Poland
Braga, , Portugal
Leiria, , Portugal
Lisboa, , Portugal
Porto, , Portugal
Santiago Compostela, , Spain
Kings Lynn, , United Kingdom
Southampton, , United Kingdom
Skokie, Illinois, United States
Barrio Gral Paz Cba Capital, , Argentina
Caba, , Argentina
Sankt Polten, , Austria
St Johns, Newfoundland And Labrador, Canada
Skierniewice, , Poland
Lisboa, , Portugal
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported